These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33826999)

  • 1. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.
    Meng GQ; Wang JS; Wang YN; Wei N; Wang Z
    Int Immunopharmacol; 2021 Jul; 96():107606. PubMed ID: 33826999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
    Chellapandian D; Das R; Zelley K; Wiener SJ; Zhao H; Teachey DT; Nichols KE;
    Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report.
    Zhu M; Zhang J; Shi Q; Sun X; Wang H; Sun M; Liu Y
    Iran J Immunol; 2023 Dec; 20(4):466-472. PubMed ID: 37873944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH.
    Shamriz O; Kumar D; Shim J; Briones M; Quarmyne MO; Chonat S; Lucas L; Edington H; White MH; Mahajan A; Park S; Chandrakasan S
    J Clin Immunol; 2021 Oct; 41(7):1582-1596. PubMed ID: 34173902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
    Yamamoto N; Nishimura N; Takeuchi M; Ito T; Yokozaki H; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Nishio H; Matsuo M; Imadome K; Iijima K
    Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of plasma Epstein-Barr virus DNA monitoring in pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: a Chinese retrospective observational study.
    Zhang W; Yin Y; Li Y; Cheng L; Zhao L; Peng Y; Wu X
    Ital J Pediatr; 2024 Jul; 50(1):139. PubMed ID: 39080799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of Virology and Immune Inflammation of Epstein-Barr Virus Infection Related Non-Neoplastic Diseases in Children.
    Wang Q; Duan Z; Duan W; Ruan M; Zhang Y; Zhang H; Zhou Q
    Clin Lab; 2024 May; 70(5):. PubMed ID: 38747912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.
    Chen R; Lin Q; Zhu Y; Shen Y; Xu Q; Tang H; Cui N; Jiang L; Dai X; Chen W; Li X
    Orphanet J Rare Dis; 2023 Sep; 18(1):297. PubMed ID: 37736751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr Virus (EBV)-induced B-cell Lymphoproliferative Disorder Mimicking the Recurrence of EBV-associated Hemophagocytic Lymphohistiocytosis.
    Yatsushiro Y; Nishikawa T; Saito A; Nakazawa Y; Imadome KI; Nakagawa S; Kodama Y; Okamoto Y; Kanegane H; Kawano Y
    J Pediatr Hematol Oncol; 2019 Jan; 41(1):e44-e46. PubMed ID: 29324572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resolution of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis associated with rapid immune reconstruction after a single course of CHOP therapy.
    Chikagawa Y; Hikishima K; Mizumaki H; Sugimori C; Nakagishi Y; Yachie A; Nakao S
    Int J Hematol; 2020 Dec; 112(6):889-893. PubMed ID: 32725606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis.
    Toga A; Wada T; Sakakibara Y; Mase S; Araki R; Tone Y; Toma T; Kurokawa T; Yanagisawa R; Tamura K; Nishida N; Taneichi H; Kanegane H; Yachie A
    J Infect Dis; 2010 Jun; 201(12):1923-32. PubMed ID: 20443735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance and different strategies for re-elevation of plasma EBV-DNA during treatment in pediatric EBV-associated hemophagocytic lymphohistiocytosis.
    Zhang W; Peng Y; Qiu Y; Cheng L; Yin Y; Li Y; Zhao L; Wu X
    J Pediatr (Rio J); 2024; 100(5):505-511. PubMed ID: 38604242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis-a dangerous disease.
    Jin Z; Wang Y; Wei N; Wang Z
    Ann Hematol; 2020 Jul; 99(7):1575-1581. PubMed ID: 32500223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review.
    Stefanou C; Tzortzi C; Georgiou F; Timiliotou C
    BMJ Case Rep; 2016 Dec; 2016():. PubMed ID: 27941111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group.
    Kogawa K; Sato H; Asano T; Ohga S; Kudo K; Morimoto A; Ohta S; Wakiguchi H; Kanegane H; Oda M; Ishii E
    Pediatr Blood Cancer; 2014 Jul; 61(7):1257-62. PubMed ID: 24535916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
    Yao S; He L; Zhang R; Liu M; Hua Z; Zou H; Wang Z; Wang Y
    Ann Med; 2023 Dec; 55(1):89-100. PubMed ID: 36533966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
    Papageorgiou SG; Tsiodras S; Siakallis G; Bazani E; Spathis A; Poulakou G; Korkolopoulou P; Panayiotides I; Pappa V
    Pathol Res Pract; 2016 Dec; 212(12):1194-1198. PubMed ID: 28340951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
    Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
    Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy.
    Tejedor I; Tedbirt B; Carvalho P; Duval-Modeste AB; Joly P; Hébert V
    Melanoma Res; 2022 Dec; 32(6):485-487. PubMed ID: 36125885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.